Re­vis­it­ing the 'cy­tokine stor­m' in ARDS; the painful wait for an­ti-in­flam­ma­to­ry drugs/tar­gets that solve Covid-19 deaths

Biotech Voices is a collection of exclusive opinion editorials from some of the leading voices in biopharma on the biggest industry questions today. Think you have a voice that should be heard? Reach out to senior editors Kyle Blankenship and Amber Tong.

I am a pul­monary and crit­i­cal care physi­cian-sci­en­tist with sub­stan­tial ex­per­tise in crit­i­cal care med­i­cine, par­tic­u­lar­ly in the in­flam­ma­to­ry path­ways in­volved in the acute res­pi­ra­to­ry dis­tress syn­drome (ARDS) and ven­ti­la­tor-in­duced lung in­jury (VILI).

As a re­sult, my lab­o­ra­to­ry has been pur­su­ing mech­a­nis­tic in­sights and ef­fec­tive ther­a­pies for ARDS and VILI for sev­er­al decades. Over this ex­pand­ed time hori­zon, there is abun­dant sup­port for the con­trib­u­to­ry role of the much dis­cussed “cy­tokine storm,” long as­so­ci­at­ed with fa­tal ARDS and now with Covid-19-as­so­ci­at­ed ARDS.

The es­sen­tial na­ture of the elab­o­rat­ed cy­tokines to Covid-19 ARDS out­comes has been ques­tioned in the me­dia and were ini­tial­ly voiced in an ed­i­to­r­i­al by UCSF ARDS ex­perts. It is ap­pro­pri­ate to con­sid­er this point of view; how­ev­er, it must be rec­og­nized that the pri­ma­ry ba­sis for this sen­ti­ment is re­lat­ed to ob­ser­va­tions cen­tered on the in­ter­leukin-6 (IL-6) path­way, well-rec­og­nized to be in­volved in ARDS patho­bi­ol­o­gy.

One ob­ser­va­tion is that me­di­an cir­cu­lat­ing IL-6 lev­els in five Covid-19 co­horts were low­er when com­pared to co­horts of non-Covid-19 ARDS, and the sec­ond ob­ser­va­tion is that sev­er­al high-pro­file tri­als tar­get­ing IL-6 re­cep­tor an­tag­o­nism in Covid ARDS failed to im­prove COVID-19 ARDS mor­tal­i­ty. Specif­i­cal­ly, the IL-6 re­cep­tor an­tag­o­nists tocilizum­ab (Roche/Sanofi) and sar­ilum­ab (Re­gen­eron/Sanofi), both failed to im­prove mor­tal­i­ty in Phase II/III clin­i­cal tri­als of Covid-19 pa­tients with se­vere dis­ease (“Cleanup on IL-6”).

In fact, tri­al ev­i­dence sug­gest­ed that drug re­cip­i­ents may be at in­creased risk for oth­er in­fec­tions, a par­tic­u­lar risk in re­gions where drug-re­sis­tant bac­te­ria are com­mon. The ac­cu­mu­lat­ed fail­ure of tar­get­ing the IL-6 path­way may re­flect sev­er­al fac­tors that are of spe­cif­ic rel­e­vance to IL-6, in­clud­ing the down­stream na­ture of this cy­tokine in the in­flam­ma­to­ry cas­cade, as well as the com­plex role of IL-6 in in­nate im­mu­ni­ty, i.e. ex­ert­ing both an­ti-in­flam­ma­to­ry and pro-in­flam­ma­to­ry ef­fects.

Over­all, I be­lieve there is wide ac­cep­tance that ARDS patho­bi­ol­o­gy is fun­da­men­tal­ly re­lat­ed to mas­sive ac­ti­va­tion of evo­lu­tion­ar­i­ly-con­served in­flam­ma­to­ry net­works by sep­sis (in­fec­tion in the blood), se­vere trau­ma, and se­vere bac­te­r­i­al or vi­ral pneu­mo­nias in­clud­ing SARS-CoV-2. This in­flam­ma­to­ry ac­ti­va­tion is sub­stan­tial­ly am­pli­fied when pa­tients are placed up­on me­chan­i­cal ven­ti­la­tion, a po­tent in­flam­ma­to­ry stim­u­lus and con­trib­u­tor to ARDS mor­tal­i­ty.

Thus, tar­get­ing of the un­remit­ting in­flam­ma­tion re­mains a crit­i­cal com­po­nent to ad­dress­ing ARDS mor­tal­i­ty, al­beit un­like­ly as a sole ther­a­peu­tic strat­e­gy. This was sup­port­ed by the Unit­ed King­dom tri­als demon­strat­ing ben­e­fit of the po­tent, non-spe­cif­ic an­ti-in­flam­ma­to­ry steroid, dex­am­etha­some, in se­vere Covid-19 ARDS.

Clear­ly, ARDS is a vex­ing dis­or­der with­out FDA-ap­proved ther­a­pies and a stag­ger­ing un­met need in the cur­rent Covid-19 pan­dem­ic land­scape. The fail­ure of many promis­ing in­flam­ma­tion-fo­cused ARDS drugs in Phase II and III tri­als, such as IL-6 an­tag­o­nists and gam­ma in­ter­fer­on ana­logues, may re­flect is­sues in: 1) tar­get se­lec­tion, i.e. cy­tokines down­stream in the in­flam­ma­to­ry cas­cade; or 2) de­lays in ad­min­is­tra­tion of the an­ti-in­flam­ma­to­ry ther­a­peu­tic, there­by re­duc­ing its in­flu­ence on damp­en­ing in­flam­ma­to­ry ac­ti­va­tion is min­i­mal.

As a physi­cian-sci­en­tist and ICU care­giv­er, I have been long search­ing for nov­el ap­proach­es to re­duc­ing ARDS mor­tal­i­ty. When serv­ing as the Di­rec­tor of Pul­monary and Crit­i­cal Care Med­i­cine at Johns Hop­kins in 2005, I first re­port­ed the iden­ti­fi­ca­tion of eNAM­PT (ex­tra­cel­lu­lar nicoti­namide phos­pho­ri­bo­syl­trans­ferase) as a mas­ter reg­u­la­tor of in­nate im­mu­ni­ty-dri­ven in­flam­ma­tion that con­tributes to ARDS mor­tal­i­ty and is es­sen­tial­ly in­volved in VILI patho­bi­ol­o­gy.

Our sub­stan­tial pre­clin­i­cal da­ta sup­port the tar­get­ing of eNAM­PT with a hu­man­ized mon­o­clon­al an­ti­body (ALT-100 mAb) to sig­nif­i­cant­ly im­pact hu­man Covid-19- and non-Covid ARDS/VILI. We are mak­ing ex­cel­lent progress in mov­ing ALT-100 mAb down the drug de­vel­op­ment pipeline and to ARDS Clin­i­cal Tri­al eval­u­a­tion.

I am to­tal­ly con­vinced that the in­creas­ing avail­abil­i­ty of nov­el strate­gies (such as ALT-100 mAb) will ul­ti­mate­ly al­low for suc­cess­ful tri­als with drugs that re­duce ARDS sever­i­ty and mor­tal­i­ty, par­tic­u­lar­ly when we be­gin to em­ploy per­son­al­ized med­i­cine strate­gies in tri­al de­sign.

I do be­lieve, how­ev­er, sim­i­lar to the man­age­ment of many can­cers, that to dra­mat­i­cal­ly move the nee­dle on re­duc­ing ARDS/VILI mor­tal­i­ty, will re­quire a com­bi­na­tion of ther­a­peu­tic ap­proach­es (in­clud­ing an an­ti-in­flam­ma­to­ry drug). The wait for an FDA-ap­proved ARDS ther­a­py or ther­a­pies has been a frus­trat­ing re­al­i­ty. I am cer­tain many will agree that giv­en the cur­rent Covid pan­dem­ic and like­li­hood of fu­ture pan­demics, we sim­ply can­not af­ford to wait any longer.

Dr. Joe G.N. Gar­cia is an elect­ed mem­ber of the Na­tion­al Acad­e­my of Med­i­cine and CEO of Aqualung Ther­a­peu­tics, an ear­ly-stage biotech com­pa­ny de­vel­op­ing an im­mune-fo­cused, an­ti-in­flam­ma­to­ry plat­form cen­tered around nov­el ther­a­peu­tic hu­man­ized an­ti­bod­ies for ARDS/VILI pa­tients.

Biotech Voic­es is a con­tributed col­umn from se­lect End­pointsNews read­ers. Read pre­vi­ous pieces here. To in­quire about sub­mis­sions, con­tact Kyle Blanken­ship at kyle@end­pointsnews.com.

The DCT-OS: A Tech­nol­o­gy-first Op­er­at­ing Sys­tem - En­abling Clin­i­cal Tri­als

As technology-enabled clinical research becomes the new normal, an integrated decentralized clinical trial operating system can ensure quality, deliver consistency and improve the patient experience.

The increasing availability of COVID-19 vaccines has many of us looking forward to a time when everyday things return to a state of normal. Schools and teachers are returning to classrooms, offices and small businesses are reopening, and there’s a palpable sense of optimism that the often-awkward adjustments we’ve all made personally and professionally in the last year are behind us, never to return. In the world of clinical research, however, some pandemic-necessitated adjustments are proving to be more than emergency stopgap measures to ensure trial continuity — and numerous decentralized clinical trial (DCT) tools and methodologies employed within the last year are likely here to stay as part of biopharma’s new normal.

Onno van de Stolpe, Galapagos CEO (Thierry Roge/Belga Mag/AFP via Getty Images)

Gala­pa­gos chops in­to their pipeline, drop­ping core fields and re­or­ga­niz­ing R&D as the BD team hunts for some­thing 'trans­for­ma­tive'

Just 5 months after Gilead gutted its rich partnership with Galapagos following a bitter setback at the FDA, the Belgian biotech is hunkering down and chopping the pipeline in an effort to conserve cash while their BD team pursues a mission to find a “transformative” deal for the company.

The filgotinib disaster didn’t warrant a mention as Galapagos laid out its Darwinian restructuring plans. Forced to make choices, the company is ditching its IPF molecule ’1205, while moving ahead with a Phase II IPF study for its chitinase inhibitor ’4617.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 104,800+ biopharma pros reading Endpoints daily — and it's free.

Stéphane Bancel, Getty

Mod­er­na CEO brush­es off US sup­port for IP waiv­er, eyes more than $19B in Covid-19 vac­cine sales in 2021

Moderna is definitively more concerned with keeping pace with Pfizer in the race to vaccinate the world against Covid-19 than it is with Wednesday’s decision from the Biden administration to back an intellectual property waiver that aims to increase vaccine supplies worldwide.

In its first quarter earnings call on Thursday, Moderna CEO Stéphane Bancel shrugged off any suggestion that the newly US-backed intellectual property waiver would impact his company’s vaccine or bottom line. Still, the company’s stock price fell by about 9% in early morning trading.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 104,800+ biopharma pros reading Endpoints daily — and it's free.

Angela Merkel (AP Photo/Michael Sohn)

Covid-19 roundup: Pfiz­er sub­mits vac­cine for full ap­proval; Merkel op­pos­es Biden pro­pos­al to sus­pend IP for vac­cines

Pfizer and BioNTech said Friday that they’ve submitted a biologics license application to the FDA for full approval of their mRNA vaccine for those over the age of 16.

How long it will take the FDA to decide on the BLA will be set once it’s been formally accepted by the agency.

Peter Marks, director of the FDA’s Center for Biologics Evaluation and Research, previously told Endpoints News that the review of the BLA should take between three and four months, but it may be even faster than that.

UP­DAT­ED: EMA safe­ty com­mit­tee seeks more in­fo on heart in­flam­ma­tion fol­low­ing Pfiz­er Covid-19 vac­cine

The European Medicines Agency’s safety committee said Friday that it’s aware of cases of inflammation of the heart muscle and inflammation of the membrane around the heart, mainly reported following vaccination with Pfizer’s Covid-19 vaccine, known in Europe as Comirnaty.

“There is no indication that these cases are due to the vaccine,” the EMA’s Pharmacovigilance Risk Assessment Committee said.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 104,800+ biopharma pros reading Endpoints daily — and it's free.

As­traZeneca caps PD-L1/CT­LA-4/chemo com­bo come­back with OS win. Is treme­li­mum­ab fi­nal­ly ready for ap­proval?

AstraZeneca’s closely-watched POSEIDON study continues to be the rare bright spot in its push for an in-house PD-L1/CTLA-4 combo.

Combining Imfinzi and tremelimumab with physicians’ choice of chemotherapy helped patients with stage IV non-small cell lung cancer live longer, the company reported — marking the first time the still-experimental tremelimumab has demonstrated an OS benefit.

For AstraZeneca and CEO Pascal Soriot, the positive readout — which is devoid of numbers — offers much-needed validation for the big bet they made on Imfinzi plus tremelimumab, after the PD-L1/CTLA-4 regimen failed multiple trials in head and neck cancer as well as lung cancer.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 104,800+ biopharma pros reading Endpoints daily — and it's free.

Ron DePinho (file photo)

A 'fly­over' biotech launch­es in Texas with four Ron De­Pin­ho-found­ed com­pa­nies un­der its belt

In his 13 years at Genzyme, Michael Wyzga noticed something about East Coast drugmakers. Execs would often jet from Boston or New York to San Francisco to find more assets, and completely miss the work being done in flyover states, like Texas or Wisconsin.

“If it doesn’t come out of MGH or MIT or Harvard, probably not that interesting,” he said of the mindset.

Now, he and some well-known industry players are looking to change that, and they’ve reeled in just over $38 million to do it.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 104,800+ biopharma pros reading Endpoints daily — and it's free.

An­oth­er failed tri­al for Or­p­hazyme's 'pipeline-in-a-pro­duc­t' leaves shad­ow on drug's fu­ture

The tumultuous ride for Orphazyme continued on Friday as the company announced that a pivotal trial for its lead drug arimoclomol failed yet again, this time in the treatment of ALS, seeding doubt in a drug that had recently been cleared by the FDA for priority review. The latest failure casts a darker shadow on the upcoming decision despite Orphazyme’s upbeat outlook.

In a statement, the Danish biotech announced that the drug did not meet its primary or secondary endpoints evaluating function and survival. But the company has not announced any data surrounding the failure, instead saying that it will publish the complete results later this year.

In­cyte ponies up $12M to set­tle char­i­ty foun­da­tion kick­back claims; US ex­er­cis­es op­tion for more dos­es of mon­key­pox vac­cine

One in a string of lawsuits targeting copay charity foundations, the DOJ has been hunting drugmaker Incyte for what prosecutors alleged was a kickback scheme to court patients. Now, Incyte is clearing its name.

Incyte will shell out $12.6 million to settle claims it funneled funds through a charity foundation to cover federal copays for patients taking its JAK inhibitor Jakafi, the DOJ said this week.